 | Up a level |
Laakmann, E., Witzel, I, Neunhoeffer, T., Park-Simon, T-W, Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lubbe, K., Hesse, T., Thill, M., Zahm, D-M, Denkert, C., Fehm, T., Nekljudova, V, Rey, J., Loibl, S. and Mueller, V (2022). Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open, 7 (3). AMSTERDAM: ELSEVIER. ISSN 2059-7029
von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445